I consider myself a 50/50 technical/fundamental trader and investor. I have carved a niche in analyzing small cap biotechnology companies and analyzing trial data, design and company structure. I mainly trade catalyst-driven stocks with good cash positions and promising therapies. Overall, my specialty is trial data. Over the past 6 years of research and investing, I have learned of the many ways to make money trading these extremely volatile and speculative biotech plays, particularly by making the best assumptions and educated guesses possible on trial data and company structure and management. I play the FDA calendar and pick the best companies possible for run-ups to data. I also do research for Stockmatusow.com, and collaborate with Scott Matusow and Kyle Dennis on articles and trade calls.
I invest for myself and my husband. I'm a realtor in Phoenix, AZ and work with the snow birds that come enjoy our sunshine!! I love the downtown Phoenix area and the urban lifestyle.
Take a look at my website www.azrealestatebydaisy.com to search the MLS and find your "lock and leave".
Bachelor of Science Microbiology The Pennsylvania State University
Master of Science Microbiology The Ohio State University
Masters in Business Administration California State University, Fresno
Tax Deferred IRA Vanguard
Deferred Compensation Plan, Great West
Investing since 1993 - Scottrade; Charles Schwab tradingplatform; Vanguard
Tobin Smith, founder/CEO of NBT Group, Inc. and Chief Research Officer NBT Equities Research LLC .Editor-In-Chief NextBigThingInvestor.com and Next Big Thing Investor Pro Newsletter. Fox News market analyst/contributor since 2000 and Fox Business Network guest anchor since 2007. NBTEquitiesEesearch.com is our sponsored research web-site. Founded ChangeWave Research LLC, one of the first expert-network primary research organizations in 1998...sold to 451 Group in 2010. NY Times bestselling investment book ChangeWave Investing 2000 and ChangeWave Investing 2.0 2002